MedTrace Logo

Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome

NCT04303962 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-01-19

No results posted yet for this study

Summary

Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient's recovery and clinical prognosis vary. The establishment of a cohort study on the therapeutic effect of gamma globulin in Guillain-barre Syndrome is beneficial to the diagnosis of the disease and to the understanding of the natural course of the disease and the efficacy of drug treatment.

Conditions

  • Guillain-barre Syndrome

Sponsors & Collaborators

  • Ning Wang, MD., PhD.

    lead OTHER

Principal Investigators

  • Ning Wang, MD · First Affiliated Hospital of Fujian Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2024-01-21
Completion
2025-01-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04303962 on ClinicalTrials.gov